On January 5, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, reported that the company will participate in the following January investor conferences (Press release, Magenta Therapeutics, JAN 5, 2022, View Source [SID1234598230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session
B. Riley Virtual Oncology Conference, on Friday, January 28th, 2022, at 11:00 a.m. ET
A live webcast of the presentations can be accessed through the Investors & Media section of Magenta’s website at View Source A replay of each webcast will be available on Magenta’s website for 30 days following the events.